Company Type

• Top 20 Pharma: 32.9%
• Small/Mid-Tier Pharma: 21.5%
• Emerging Biopharma: 11.4%
• Virtual Pharma: 7.4%
• Generic Pharma: 6.7%
• Top 10 Biopharma: 6.0%
• Specialty Pharma: 5.4%
• Consumer/OTC Healthcare: 1.3%
• Other: 7.4%

Job Function

• R&D: 22.8%
• Purchasing/Sourcing: 12.1%
• Production/Manufacturing/Packaging: 9.4%
• Corporate Management: 8.7%
• QA/QC/Validation: 8.1%
• Project Manager: 7.4%
• Supply Chain Manager: 6.7%
• Contract Manager: 5.4%
• Business Development: 4.7%
• Marketing/Sales: 3.4%
• Clinical Research: 2.7%
• Engineering: 2.0%
• Regulatory Affairs: 0.7%
• Other: 6.0%

Signs of Improvement?

Last year, a whopping 55% of total respondents believed that they’d spend the same or less on outsourcing spending in the coming year; this year, that dipped to 45%.Meanwhile, 51%, told us that they spent the same or less on outsourcing in the previous year, down from 56%in our 2010 survey.

Only 25% of respondents told us they had cancelled outsourcing projects in the previous year due to the economy; down from 35% in our 2010 survey. Half of those respondents said they foresee resuming those projects with the original contract service provider, and 75% of them describe their outsourcing as strategic, not tactical. (Only 56% of all respondents describe their outsourcing relationships as strategic.)